RxDoctor Payments Data

Aron Rosenstock, MD

Medical Oncology · Houston, TXNPI 1619105830

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$184,192in research payments, 2019–2025

Across 17 payments — averaging $10,835 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$132K
  • Sanofi US Services Inc.$49K
  • Merck$3K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Medicare billing

Part B allowed, 2024
$116,750
Medicare patients
388
Services billed
1,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib43$638,287
VerzenioAbemaciclib24$347,191
Exemestane43$9,103
EliquisApixaban15$8,760
Anastrozole336$7,233
Letrozole42$769
Tamoxifen Citrate24$753
Gabapentin23$62

Paid to pharmacies, not to this prescriber.

Other medical oncology in Houston

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →